1 Patient Report 

  
Specimen ID: 043-P75-0103-0 Acct #: 04517392 Phone: (951) 929-9688 Rte: 00
Control ID: C5F04517392
CA Imaging and Diagnostics
CASTELLANO, SANDRA 850 E Latham Ave Ste 101
206 GALLEY CT Hemet CA 92543
























SAN JACINTO CA 92583
(951) 566-6533

Patient Details Specimen Details Physician Details

DOB: 02/23/1966 Date collected: 02/11/2020 0355 Local Ordering: WAREHAM
Age(y/m/d): 053/11/19 Date received: 02/12/2020 Referring:
Gender: F SSN: ***-**-3226 Date entered: 02/12/2020 ID:
Patient ID: 090685 Date reported: 02/14/2020 2135 ET NPI: 1558335471
Additional Information:
Clinical Info: CO-LWS20206924

Tests Ordered: Clinician Provided ICD Code(s) & Clinical History: (01)
Pathology Report
9/10-g (1 o'clock clip).
Material Submitted: (01)
Gross Description: (01)
breast - LEFT BREAST, STEREOTACTIC CORE BIOPSY.
Modifiers: left 1 Container, formalin-filled, labeled with patient identification.
LEFT BREAST, STEREOTACTIC CORE BIOPSY:
Diagnosis: (01) Received labeled "L BREAST".
The specimen consists of multiple needle cores of tan tissue ranging
LEFT BREAST, STEREOTACTIC CORE BIOPSY: in length from 0.3 to 1.2 cm, measuring 0.1 cm in diameter. The
- HIGH-GRADE DUCTAL CARCINOMA IN SITU specimen is wrapped and entirely submitted in 4 cassette(s).
(PREDOMINANTLY COMEDO TYPE AND CRIBRIFORM /MEK 02/12/2020 0425 Local
TYPE), NUCLEAR GRADE 3/NUCLEAR GRADE 1-3. -
MICROCALCIFICATION WITHIN DUCTAL CARCINOMA IN
SITU IDENTIFIED. - Tumor cells show membrane positivity
for E-Cadherin and p120 (with appropriate controls).
- Tumor cells are negative for synaptophysin and CK5/6 (with
appropriate controls).
- Immunohistochemistry staining pattern for ADH5 and p63
(with appropriate controls) support the above diagnosis.
- ADDITIONAL FINDING: SMALL INTRADUCTAL
PAPILLOMA.
-
_____________________________________
BREAST PROGNOSTIC MARKER ANALYSIS:
-
ESTROGEN RECEPTOR: NEGATIVE
- Percent: Less than 1%.
- Analysis: Manual
- Staining Intensity: Weak to moderate
-
PROGESTERONE RECEPTOR: NEGATIVE
- Percent: 0%

(01) LCMON LabCorp Monrovia 605 East Huntington Drive Ste Monrovia CA 91016-6353 Lab: 626-471-3500 Dir: Mona Yong, MD
209

For inquiries, the physician may contact the lab using the numbers indicated above:
Date Issued: 02/19/20 2149 ET FINAL REPORT Page 1 of 3
This document contains private and confidential health information protected by state and federal law. © 1995-2020 Laboratory Corporation of America® Holdings
If you have received this document in error, please call 626-471-3500 All Rights Reserved - Enterprise Report Version: 1.00
         
1 Patient Report   
Patient: CASTELLANO, SANDRA Specimen ID: 043-P75-0103-0
DOB: 02/23/1966 Patient ID: 090685 Control ID: C5F04517392 Date collected: 02/11/2020 0355 Local

Diagnosis: (continued) (01)

- Analysis: Manual
- Staining Intensity:
-
Fixation Comment: Time of Fixation (cold ischemic time): Less
than 1 hour.
Duration of Fixation: Less than 72 hours.
Type of fixative: 10% neutral Buffered Formalin.
-
COMMENT:
Dr Tan has reviewed this case and concurs with the above
diagnosis. The diagnosis is reported to Carrie D. at CA
Imaging and Diagnostics by Dr Hong Li on 02/14/20.
Report will be faxed.
______________________
TECHNICAL NOTE:
The scoring criteria for breast biomarkers by
immunohistochemistry is based on the current ASCO/CAP
guidelines (Hammond et al, Arch Pathol Lab
Med 2010: 134(6): 907-922 / Wolff AC et al, Arch Pathol Lab
Med 2014:
138(2): 241-256). Deparaffinized sections of formalin fixed
tissue (along
with appropriate positive controls) are incubated with the
above antibody(s). Using the automated Leica Bond stainer,
tissue is incubated with the designated antibody* which is
then localized by a non-biotin, polymer detection system. The
external/internal controls are reviewed for appropriate
reactivity and found to be adequate. Results on the target cell
population are indicated above. These tests have not been
validated on decalcified tissue. * This test was developed and
its performance characteristics determined by LabCorp. It has
not been cleared or approved by the U.S. Food and Drug
Administration. The FDA has determined that such clearance
or approval is not necessary. This test is used for clinical
purposes. It should not be regarded as investigational or for
research. LEN 02/14/2020 1813 Local

Pathologist Provided ICD Code(s): (01)

D05.92
CPT Codes: (01)
883051, W30001, W20061, W20532, 883601, 883602

Date Issued: 02/19/20 2149 ET FINAL REPORT Page 2 of 3

This document contains private and confidential health information protected by state and federal law. © 1995-2020 Laboratory Corporation of America® Holdings
If you have received this document in error, please call 626-471-3500 All Rights Reserved - Enterprise Report Version: 1.00
         
1 Patient Report   
Patient: CASTELLANO, SANDRA Specimen ID: 043-P75-0103-0
DOB: 02/23/1966 Patient ID: 090685 Control ID: C5F04517392 Date collected: 02/11/2020 0355 Local

Comments: (01)
Note: The immunohistochemical stain(s) reported was developed and its performance characteristics determined by LabCorp Inc. with
appropriate controls for each antibody. It has not been cleared or approved by the U.S. Food and Drug Administration, although such
approval is not required for analyte-specific reagents of this type.

Electronically signed by (01)

Hong Li, MD, Pathologist

Date Issued: 02/19/20 2149 ET FINAL REPORT Page 3 of 3

This document contains private and confidential health information protected by state and federal law. © 1995-2020 Laboratory Corporation of America® Holdings
If you have received this document in error, please call 626-471-3500 All Rights Reserved - Enterprise Report Version: 1.00